(VIANEWS) – Amphastar Pharmaceuticals (AMPH), LGI Homes (LGIH), ProLogis (PLD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Amphastar Pharmaceuticals (AMPH)
45.4% sales growth and 18.12% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $1.74.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 36.09. Meaning, the purchaser of the share is investing $36.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.12%.
Moving Average
Amphastar Pharmaceuticals’s worth is way higher than its 50-day moving average of $53.40 and way above its 200-day moving average of $38.11.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Amphastar Pharmaceuticals’s EBITDA is 51.85.
Previous days news about Amphastar Pharmaceuticals(AMPH)
- According to Zacks on Thursday, 17 August, "Sales of rights to some products (olanzapine portfolio, including Zyprexa, to Cheplapharm Arzneimittel and Baqsimi to Amphastar Pharmaceuticals [(AMPH Quick QuoteAMPH – Free Report) ]) coupled with an improved underlying performance led to the guidance increase."
- According to Zacks on Friday, 18 August, "In the year-to-date period, shares of Amphastar Pharmaceuticals (AMPH Quick QuoteAMPH – Free Report) have shot up 89.1% compared with the industry’s 32.4% climb. "
2. LGI Homes (LGIH)
45.1% sales growth and 12.61% return on equity
LGI Homes, Inc. designs, constructs, and sells homes in the United States. It offers entry-level homes, such as detached and attached homes, and move-up homes under the LGI Homes brand name; and luxury series homes under the Terrata Homes brand name. As of December 31, 2020, it owned 113 communities. The company serves in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia, and Pennsylvania. LGI Homes, Inc. was founded in 2003 and is headquartered in The Woodlands, Texas.
Earnings Per Share
As for profitability, LGI Homes has a trailing twelve months EPS of $11.69.
PE Ratio
LGI Homes has a trailing twelve months price to earnings ratio of 11.52. Meaning, the purchaser of the share is investing $11.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.61%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
LGI Homes’s EBITDA is 2.03.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 40.5% and positive 75.9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 10.8%, now sitting on 2.17B for the twelve trailing months.
Previous days news about LGI Homes(LGIH)
- According to Zacks on Thursday, 17 August, "Some better-ranked stocks from the broader real estate industry are KE Holdings (BEKE Quick QuoteBEKE – Free Report) , LGI Homes (LGIH Quick QuoteLGIH – Free Report) and Forestar Group (FOR Quick QuoteFOR – Free Report) . ", "The Zacks Consensus Estimate for LGI Homes 2023 EPS has been raised 7.5% over the past month to $8.14."
3. ProLogis (PLD)
12.4% sales growth and 7.15% return on equity
Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At June 30, 2023, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (114 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 6,700 customers principally across two major categories: business-to-business and retail/online fulfillment.
Earnings Per Share
As for profitability, ProLogis has a trailing twelve months EPS of $3.2.
PE Ratio
ProLogis has a trailing twelve months price to earnings ratio of 38.51. Meaning, the purchaser of the share is investing $38.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.15%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 14, 2023, the estimated forward annual dividend rate is 3.48 and the estimated forward annual dividend yield is 2.82%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ProLogis’s EBITDA is 18.36.
Yearly Top and Bottom Value
ProLogis’s stock is valued at $123.22 at 01:22 EST, way under its 52-week high of $138.86 and way higher than its 52-week low of $98.03.
4. Boston Scientific (BSX)
11.9% sales growth and 5.1% return on equity
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Per Share
As for profitability, Boston Scientific has a trailing twelve months EPS of $0.59.
PE Ratio
Boston Scientific has a trailing twelve months price to earnings ratio of 86.36. Meaning, the purchaser of the share is investing $86.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.1%.
Moving Average
Boston Scientific’s value is below its 50-day moving average of $52.36 and above its 200-day moving average of $48.77.
5. CIRCOR International (CIR)
8.5% sales growth and 21.76% return on equity
CIRCOR International, Inc. designs, manufactures, and distributes flow and motion control products. The company has a product portfolio of brands serving its customers' demanding applications. It operates through two segments, Aerospace & Defense and Industrial. The Aerospace & Defense segment manufactures and markets control valves, pumps, regulators, fluid controls, actuation systems, pneumatic valves and controls, electro-mechanical controls, motors, and other flow control products and systems. Its products and services are used in the military and defense, commercial aerospace, business and general aviation, and general industrial markets, as well as serves aircraft manufacturers and tier 1 suppliers. This segment offers its products under the CIRCOR Aerospace, Aerodyne Controls, CIRCOR Bodet, CIRCOR Industria, CIRCOR Motors, Hale Hamilton, Leslie Controls, Portland Valve, and Warren Pumps brands. The Industrial segment provides 3 and 2 screw pumps, progressing cavity pumps, specialty centrifugal pumps, and gear metering pumps; automatic recirculation valves; general service control valves; and pipeline pigs and closures for the end-users and original equipment manufacturers, as well as engineering, procurement, and construction companies. This segment offers its products under the Allweiler, Houttuin, IMO Pump, IMO AB, Leslie Controls, RG Lawrence, RTK, Schroedahl, Tushaco, and Zenith brands. The company has operations in Europe, the Middle East, Africa, North America, and internationally. The company markets its solutions directly and through various sales partners to approximately 14,000 customers in approximately 100 countries. CIRCOR International, Inc. was incorporated in 1999 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, CIRCOR International has a trailing twelve months EPS of $1.98.
PE Ratio
CIRCOR International has a trailing twelve months price to earnings ratio of 28.09. Meaning, the purchaser of the share is investing $28.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.76%.
6. UFP Technologies (UFPT)
8.5% sales growth and 21.23% return on equity
UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.
Earnings Per Share
As for profitability, UFP Technologies has a trailing twelve months EPS of $6.07.
PE Ratio
UFP Technologies has a trailing twelve months price to earnings ratio of 30.03. Meaning, the purchaser of the share is investing $30.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.23%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
UFP Technologies’s EBITDA is 3.73.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 41.8% and positive 24.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6%, now sitting on 386M for the twelve trailing months.
7. Allegiant Travel Company (ALGT)
5.6% sales growth and 5.34% return on equity
Allegiant Travel Company, a leisure travel company, provides travel services and products to residents of under-served cities in the United States. The company offers scheduled air transportation on limited-frequency, nonstop flights between under-served cities and leisure destinations. As of February 14, 2022, it operated a fleet of 110 Airbus A320 series aircraft. The company also provides air-related services and products in conjunction with air transportation, including baggage fees, advance seat assignments, travel protection products, priority boarding, a customer convenience fee, food and beverage purchases on board, and other air-related services, as well as use of its call center for purchases. In addition, it offers third party travel products, such as hotel rooms and ground transportation, such as rental cars and hotel shuttle products; and air transportation services through fixed fee agreements and charter service on a year-round and ad-hoc basis. Further, the company operates a golf course. Allegiant Travel Company was founded in 1997 and is based in Las Vegas, Nevada.
Earnings Per Share
As for profitability, Allegiant Travel Company has a trailing twelve months EPS of $3.58.
PE Ratio
Allegiant Travel Company has a trailing twelve months price to earnings ratio of 33.11. Meaning, the purchaser of the share is investing $33.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.34%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 29.9%, now sitting on 2.45B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Allegiant Travel Company’s EBITDA is 27.75.
Volume
Today’s last reported volume for Allegiant Travel Company is 50501 which is 74.17% below its average volume of 195570.
